Dr. Carlos Barcenas, MD, MSc provides an overview of biomarker testing in breast cancer, including common biomarkers, additional testing options, and how results can guide treatment decisions. He also explains the difference between biomarker and genetic testing, addresses barriers to testing, and highlights key takeaways for patients.
- 0:00:15 What is a biomarker?
- 0:01:43 What are the common biomarkers in breast cancer that are present on a pathology report?
- 0:04:35 What are other biomarkers or molecular tests used beyond the pathology report?
- 0:07:30 What biomarkers are used to guide treatment in metastatic breast cancer?
- 0:09:09 What is genetic testing and how is a biomarker different from genetic testing?
- 0:11:24 What are the differences between biomarkers and genetic testing?
- 0:12:31 Is biomarker testing standard for all breast cancer diagnosis?
- 0:13:31 Why and when are these tests recommended?
- 0:16:38 What are common barriers to biomarker testing?
- 0:17:47 What are key take aways?
Carlos H Barcenas, MD, MSc
Associate Professor in the Department of Breast Medical Oncology
Medical Director of the Breast Survivorship Clinic
The University of Texas MD Anderson Cancer Center
Carlos H Barcenas, MD, MSc, has an interest in breast cancer translational research, epidemiology, and cancer outcomes, and has published over 70 peer-reviewed manuscripts. Dr. Barcenas was awarded with the Paul Calabresi Career Development Award for Clinical Oncology (K12) for proposing the development of molecular surveillance programs measuring circulating tumor DNA (ctDNA) in patients with early breast cancer and designing clinical trials to optimize adjuvant systemic therapies guided by molecular residual disease (MRD).
